EN DE
Watch Moolec Science SA Ordinary Shares for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Moolec Science SA (MLEC) fair value: what the stock is really worth

As of Nov 2, 2026: fair value (intrinsic value) of Moolec Science SA stock $0.91, price $0.85, upside +7.4%, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN KYG6223S1259

MS Moolec Science SA logo Thin data Nov 10, 2026

Moolec Science SA

MLEC · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Ranks above peers (5/7)
Fair value $0.9128 · Fairly valued
Quality 42/100
Mixed Growth (revenue YoY +5830.7 %/yr in USD)
Negative equity (buybacks among others)
Loss-making · -33.4% net margin (FY2025)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Moolec Science SA Ordinary Shares for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2,888 $0.8500 Fair Value $0.9128 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.8500 – $2,888 · fair‑value band $0.6846 – $1.14 · the $0.8500 price screens below the $0.9128 fair value. As of Nov 10, 2026.

Follow Moolec Science SA Ordinary Shares in your weekly email

Every Wednesday you see whether Moolec Science SA Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally.

Show moreShow less

It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.

Stock analysis

Moolec Science SA (MLEC) currently trades at $0.8500, while our estimate is $0.9128, so the stock looks roughly fairly valued today (gap 6.9%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.6846 (bear) to $1.14 (bull), the price of $0.8500 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Moolec Science SA Ordinary Shares reported revenue of $334M in FY2025 versus $0 in FY2022. Reported net income was −$111M in FY2025.

Key figures

Market cap $995K Micro · P/S ratio 0.13 · EPS (TTM) $−199.02 · Net margin −33.4% · Return on equity −175% · Return on assets (EBIT) −17.8% (5-year average) · Revenue growth (YoY) +948% · Free cash flow −$30.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 7%, MLEC screens cheaper than that median.

Fair Value

Bear $0.6846 Fair Value $0.9128 Bull $1.14
Price $0.8500 · Upside +7.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 50
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 0
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MLEC, get fair value alerts →

Compare Moolec Science SA Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside +7.4% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −54.5% · Bottom 25%
Net margin (12 months) −33.4% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 948.3% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 0.13× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)43 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs MLEC
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs MLEC
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs MLEC
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs MLEC
argenx SE ARGX $971.55 $908.40 −7% vs MLEC
CSL Limited CSL A$201.68 A$181.40 −10% vs MLEC
Moderna, Inc MRNA $250.83 $158.70 −37% vs MLEC
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs MLEC
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs MLEC
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs MLEC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Moolec Science SA Ordinary Shares: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Moolec Science SA Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/MLEC

Frequently asked questions

Is Moolec Science SA (MLEC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.9128 versus the last price from Nov 2, 2026 of $0.8500, about +7% upside (fairly valued).
What is the fair value of MLEC?
Our estimate for Moolec Science SA is $0.9128 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Nov 2, 2026): $0.8500.
What is the quality score of MLEC?
Moolec Science SA has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Moolec Science SA (MLEC)?
Our calculated price target is the estimate of $0.9128 (as of Nov 10, 2026). Cautious scenario $0.6846, optimistic scenario $1.14. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Moolec Science SA Ordinary Shares stock forecast for 2026?
Our estimate puts fair value at $0.9128, about +7% upside versus the last price from Nov 2, 2026 of $0.8500 (fairly valued). Cautious scenario $0.6846, optimistic scenario $1.14. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Moolec Science SA (MLEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Moolec Science SA it is $0.9128 per share (as of Nov 10, 2026), against a price of $0.8500.
Is Moolec Science SA Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MLEC trades below its calculated fair value: price $0.8500, fair value $0.9128, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MLEC?
No. The price is what the market pays today ($0.8500); the fair value is what the company's own numbers justify ($0.9128). For Moolec Science SA the two are $0.0628 per share apart. That gap is exactly why we show both numbers side by side.
How much is Moolec Science SA Ordinary Shares worth?
The market values Moolec Science SA at about $995K (market capitalisation, as of Nov 10, 2026). Per share that is $0.8500; our models calculate a fair value of $0.9128 per share.
What do the bullish and bearish scenarios say about MLEC?
Our models span a range for Moolec Science SA: cautious scenario $0.6846, base $0.9128, optimistic $1.14 per share (as of Nov 10, 2026, price $0.8500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Moolec Science SA (MLEC)?
Balance-sheet figures for Moolec Science SA (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is MLEC from its 52-week high?
Moolec Science SA trades at $0.8500, about 95% below its 52-week high of $17.10 and at the low of $0.8500 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9128 is for.
Which stocks are comparable to Moolec Science SA Ordinary Shares?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Moolec Science SA Ordinary Shares stock attractive at the current price?
The data as of Nov 10, 2026: price $0.8500, calculated fair value $0.9128 (+7%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Moolec Science SA currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Moolec Science SA (MLEC)?
The latest price we hold is from Nov 2, 2026 and stands at $0.8500. Our estimate is $0.9128, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Moolec Science SA Ordinary Shares right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Moolec Science SA

How large is the market capitalisation of Moolec Science SA (MLEC)?
The market capitalisation of Moolec Science SA is $995K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Moolec Science SA (MLEC)?
The price-to-sales ratio of Moolec Science SA is 0.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Moolec Science SA (MLEC)?
Earnings per share at Moolec Science SA are $−199.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Moolec Science SA (MLEC)?
The net margin of Moolec Science SA is −33.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Moolec Science SA (MLEC)?
The return on equity (ROE) of Moolec Science SA is −175% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Moolec Science SA (MLEC)?
On an EBIT basis the return on assets of Moolec Science SA is −17.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Moolec Science SA (MLEC)?
Revenue at Moolec Science SA is growing +948% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Moolec Science SA (MLEC) generate?
The free cash flow of Moolec Science SA is −$30.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Moolec Science SA (MLEC) carry?
The net debt of Moolec Science SA is $246M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Moolec Science SA Ordinary Shares in the live analysis

One click puts Moolec Science SA Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.